Perimetry Based on Eye-movements in Patients With (Supra)Sellar Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-08-01

Study Completion Date

2026-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess wether the SONDA visual field test is suitable for patients with a supra sellar tumour.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Predictive Factors of Vision Recovery in Patients With Pituitary Tumor

NCT01377701

Pituitary Adenomas

UNKNOWN

Application of Augmented Reality Neuronavigation in Transnasal Endoscopic Skull Base Surgery

NCT06282224

Pituitary Neoplasms

RECRUITING NA

Clinical Study of Structural and Functional Evaluation of the Visual Pathway

NCT03591315

Pituitary Adenoma Visual Impairment Sellar Tumor +1 more

UNKNOWN

Prediction of Sphenoid Septation in MRI Compared With CT and Intraoperative Findings During Endoscopic Pituitary Adenoma Surgery

NCT03624114

Pituitary Adenoma

COMPLETED

Evaluation of the Variation Over Time of Visuospatial Deficit in Patients With Parietal Lobe Glioma

NCT07286929

Glioma Parietal Lobe Glioma Visuspatial Deficit +1 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to determine whether SONDA is non-inferior in predicting visual field limitations compared to the SAP in patients with a (supra)sellar tumor. The study population will be made up of patients with a (supra)sellar tumor complicated by compression of the optic chiasm as well as healthy controls. The patients will be asked to join the study when the patients are referred to the UMCG for further diagnostics and treatment. In case the patients show signs of visual field loss the patients will be asked to participate in the study. The researchers will reuse data from healthy controls collected in previous studies where possible and, if necessary for age matching, recruit new participants. Participants will be asked to perform the SONDA test before and after surgery. The first time the participants will perform the test twice and will also perform routine eye test and be asked to fill in a questionnaire to evaluate the experience.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pituitary Tumor Visual Fields Hemianopsia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

Participants will undergo a visual acuity test. Next they will perform the SONDA test 2 times at one visit and once more in a later visit Participants will fill in a questionnaire

SONDA

Intervention Type DIAGNOSTIC_TEST

Perimetry based visualfield analysis

Healthy controls

Participants will perform the SONDA test 2 times

SONDA

Intervention Type DIAGNOSTIC_TEST

Perimetry based visualfield analysis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SONDA

Perimetry based visualfield analysis

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with a (supra)sellar tumor
* Visual field loss based on the most recent SAP; False positive rate \<15%; fixation losses \<20%
* Informed written consent